Q1 EPS Estimates for Gossamer Bio Decreased by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for Gossamer Bio in a research note issued on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.16) per share for the quarter, down from their prior estimate of ($0.15). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS and FY2027 earnings at ($0.04) EPS.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). The business had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million.

Separately, Wedbush reiterated an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $9.20.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $1.39 on Thursday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The company has a market cap of $315.84 million, a PE ratio of -4.34 and a beta of 1.86. The company’s fifty day simple moving average is $1.16 and its 200-day simple moving average is $0.98. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.55.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio during the third quarter valued at about $67,000. The Manufacturers Life Insurance Company grew its stake in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after purchasing an additional 74,920 shares in the last quarter. Monaco Asset Management SAM increased its holdings in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Gossamer Bio by 30.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after purchasing an additional 442,895 shares in the last quarter. Finally, Octagon Capital Advisors LP boosted its stake in shares of Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after buying an additional 9,162,117 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.